Euroz Hartleys research: What Does Success Look Like?

Euroz Hartleys has published research examining expected outcomes from Cynata's two upcoming clinical readouts, describing them as "the most significant catalysts for the company in several years."

Analyst Seth Lizee maintains a Speculative Buy rating with $0.87 price target (unrisked: $1.81), based entirely on the aGvHD program. For the Phase 2 aGvHD trial (results expected June 2026), the research estimates a 60-70% Day 28 Overall Response Rate with durability through Day 100 would represent a clinically and commercially meaningful outcome, noting this compares favourably to standard of care steroids which deliver initial response in only ~50% of newly diagnosed patients. The analysis highlights that Cynata's prior Phase 1 in the harder-to-treat steroid-resistant population showed 67% ORR at Day 28 improving to 73% at Day 60. For the Phase 3 osteoarthritis trial (results expected May 2026), Euroz Hartleys suggests that while the trial has co-primary endpoints, a meaningful pain benefit versus placebo, with or without a cartilage benefit—would justify advancing the program and likely attract commercial interest.

Read the full report below.